US-CHINA: Staring into the abyss

China’s NPC: Big policies, bigger market moves?

Key points:

  • Growth and inflation: China is expected to maintain a 5% GDP growth target, while lowering its inflation target to around 2% to combat deflation risks. This signals a steady push for economic stability through targeted stimulus.
  • Consumption boost: Fiscal policies, including consumer subsidies, pension increases, and tax incentives, could aim to revive sluggish domestic demand. Retail, e-commerce, and consumer discretionary sectors may see renewed momentum on such policy focus.
  • AI innovation: China’s drive for tech self-sufficiency could lead to increased support for AI, semiconductors, and cloud computing. Major players like Alibaba, Tencent, Baidu, and SMIC could benefit from expanded policy backing.

China’s National People’s Congress (NPC) kicks off this week, and investors are watching closely for policy signals that could shape the market. While sluggish domestic demand, persistent deflation, and property sector challenges remain key concerns, rising trade tensions and geopolitical risks are also in focus.

That means macroeconomic targets, fiscal policy, and sector-specific initiatives will be under intense scrutiny. Here is a breakdown of what to expect, and which stocks might be in focus.

Growth target: Holding the line at 5%

Beijing is expected to set an “around 5%” GDP growth target for 2025, reaffirming its commitment to economic stability.

While this isn’t a surprise, it suggests continued government support for key industries. Infrastructure, consumer spending, and tech innovation are likely priorities.

Inflation target: Limiting deflation tolerance

China is expected to lower its inflation target from 3% to around 2%, emphasizing price stability.

For perspective, China’s inflation was just 0.2% in 2024, so reaching 2% in 2025 is more about restoring normal levels than controlling overheating as was the case is prior years with inflation target set at “no more than 3%”. The shift signals a steady focus on reviving consumption and eliminating deflation risks, reinforcing the need for stimulus.

Fiscal policy: Spending to support growth

Analysts widely anticipate Beijing will announce an official deficit ratio of 4% of GDP, up from the long-maintained threshold of around 3% – with notable exceptions in 2020 and 2023.

However, policymakers may also hold back large-scale stimulus in the near term to preserve flexibility in responding to external risks later in the year. That said, fiscal spending is likely to focus on:

  1. Boosting consumption and domestic demand, potentially through subsidies, pension increases, and stimulus grants.
  2. Stabilizing the struggling property sector, though structural reforms are needed for a long-term fix.
  3. Accelerating private tech innovation, especially in AI and semiconductors.
  4. Infrastructure investment, particularly if China sticks to its 5% growth target.

Sector-specific policies & stock focus

1. Consumer & e-commerce

Retail and consumer discretionary stocks could benefit from consumer stimulus measures aimed at reviving demand.

  •  Alibaba (BABA), JD.com (JD), and Pinduoduo (PDD) may see positive sentiment if subsidies or tax breaks are introduced.

2. Technology & AI

China’s push for technological self-sufficiency could lead to further investment in semiconductors and AI development. We discussed the key players in the China tech space in this article.

  • Semiconductor Stocks: Look at SMIC (0981.HK) and Hua Hong Semiconductor (1347.HK) for potential moves if chip industry support is expanded.
  • AI & Cloud Computing: Tencent (0700.HK) and Baidu (BIDU) could be in focus given their AI investments.

3. Green energy & electric vehicles (EVs)

Continued investment in clean energy and EV adoption could spur gains in this sector.

  • EV Makers: BYD (1211.HK) and XPeng (XPEV) could be in focus if there are further subsidies or policy support for new energy vehicles.
  • Battery Tech: Contemporary Amperex Technology (300750.SZ) (CATL) is a key player in China’s battery supply chain.

4. Healthcare & aging population

Healthcare remains a long-term priority, with a growing elderly population driving demand for medical services.

  • Pharma & Biotech: Wuxi Biologics (2269.HK) and CSPC Pharmaceutical (1093.HK) could benefit from policy tailwinds.

Risk of under-delivery

While the NPC will likely reinforce China’s policy direction, the real question is whether rhetoric turns into concrete action. Markets have already seen a strong year-to-date rally, which could lead to a correction if policy announcements fail to meet expectations.

Additionally, tariff risks are rising, and geopolitical uncertainties could weigh on sentiment. Investors should watch not just for what’s announced—but how quickly and effectively it’s implemented.

Disclaimer

Confidentiality and Usage:
You may not reproduce, distribute, or transmit this material or any portion thereof without prior written permission from Saxo.

Nature of Information:
The information provided herein is based on current market conditions and analysts' opinions, which may reflect personal views of the author, and are subject to change without notice. This material does not include a record of any trading prices, or an offer of, or solicitation for, or endorsement to enter into any transaction in any investment product. Any forecast on the economy, markets and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the investment product subject of this material.

Responsibility and Liability:
Saxo accepts no liability for any use that may be made of these comments or for any consequences that arise from such use. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The information provided in this material is solely for information only. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning specific situations of any person. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase an investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether any investment product mentioned in this publication is suitable for you.

Notwithstanding the above, insofar as any information provided herein contains research analyses or reports concerning any investment product authored by any foreign research house and is issued or promulgated to a person in Singapore who is not an accredited investor, expert investor, and/or institutional investor, Saxo Capital Market Pte. Ltd. accepts legal responsibility for the contents of this material to the extent required by law. Recipients of such material are to contact Saxo Capital Markets Pte. Ltd. in respect of any matters arising from, or in connection with, this material.

Risk Disclosure:
Trading in investment products involve significant risk, including the risk of losing your entire investment. Historical returns are not a guarantee of future returns. Prices can both rise and fall, and there is a risk that you will not get back the money you invested.

Conflicts of interest:
The author may hold positions in the investment products mentioned. The author does not own positions in the underlying investment product exceeding 0.5% of its market capitalisation, save as otherwise declared. The author is not permitted to trade the mentioned investment products within the first 24 hours after the publication of this article.

Saxo maintains partnerships with companies that compensate Saxo for promotional activities conducted on its platform. Additionally, Saxo has agreements with certain partners who provide retrocession contingent upon clients purchasing specific investment products offered by these partners. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Publication details:
If any listed companies are the subject of the material, the content has not been submitted to the companies in question prior to publication.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Saxo is part of the J. Safra Sarasin Group.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.